EUVIMEDEUVIMED entdecken
Crossref

Antiangiogenic effect of circulating extracellular vesicles in acute coronary syndrome: Role of miR‐199a‐3p and miR‐125a‐5p

Joaquin Bobi, Francisco-Rafael Jimenez-Trinidad, Luis Ortega-Paz, Nuria Cortes-Serra, Iolanda Lazaro iD, Juan-Jose Rodriguez iD, Carmen Fernandez-Becerra, Ana García-Álvarez, Manel Sabate, Salvatore Brugaletta, Ana-Paula Dantas iD

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Joaquin Bobi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain. Hauptthemen laut MEDLINE: MicroRNAs, Extracellular Vesicles, Acute Coronary Syndrome, Endothelial Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Sociedad Española de Cardiología, Ministerio de ciencia Innovacion y Universidades.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Circulating extracellular vesicles (EVs) have a great impact on human health as biomarkers and messengers in intercellular signalling. We aimed to determine how the miRNA profile of circulating EVs during an acute coronary event interferes with the vasculogenic potential of endothelial cells (EC). Approach and Results EVs were purified from the plasma of patients in the acute phase of non‐ST segment elevation myocardial infarction (NSTEMI, n = 33) and from healthy donors ( n = 19) used as a control group. Human ECs were treated with EV suspension (5 × 10 7 particles/cm 2 ) and tested for their vasculogenic potential and mRNA expression. The EV miRNA profile was determined by miRNA array. EV levels were markedly increased in the plasma of NSTEMI (2.3 × 10 11 ± 1.5 × 10 10 particles/mL) versus control (1.2 × 10 11 ± 1.1 × 10 10 particles/mL; p = .02). Treatment of ECs with control EVs increased migration, tube formation, and shaped more branched vessel‐like structures in comparison to Sham‐treated ECs. Nevertheless, EVs from NSTEMI lacked their vasculogenic potential. Network analysis of EV miRNA and EC mRNA expression revealed a correlation of increased miR‐199a‐3p and miR‐125a‐5p expression with a decrease in components involved in EC sprout and stabilization. Combined therapy with miR‐199a‐3p and miR‐125a‐5p decreased EC vasculogenic potential. Moreover, anti‐miRNA therapy with a combination of anti‐miR‐125a‐5p and anti‐miR‐199a‐3p restored the vasculogenic potential impaired by NSTEMI EVs.

Conclusions

Circulating EVs play an important role in the control of angiogenesis. However, in the acute phase of NSTEMI, intercellular communication via EV is modified and loses its ability to generate new blood vessels. The loss of angiogenic capacity of EVs during NSTEMI may be an important player in the disease progression and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsExtracellular VesiclesAcute Coronary SyndromeEndothelial CellsNon-ST Elevated Myocardial InfarctionNeovascularization, PhysiologicHumansMaleFemaleMiddle AgedAgedCell MovementCase-Control StudiesHuman Umbilical Vein Endothelial Cells

Stichwörter der Autor:innen

acute coronary syndromeangiogenesisextracellular vesiclesmiRNA profile

Substanzen

MicroRNAsMIRN125 microRNA, humanmirn199 microRNA, human

Autor:innen und Institutionen

  • Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain.
  • Institut Clínic Cardiovascular (ICCV), Hospital Clínic, Barcelona, Spain.
  • Department of Biomedicine, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • ISGlobal, Barcelona Institute for Global Health, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
  • IGTP Institut d'Investigació Germans Trias I Pujol, Badalona, Barcelona, Spain.
  • CIBERINFEC, ISCIII - CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.

ORCID-Profile: Iolanda Lazaro, Juan-Jose Rodriguez, Ana-Paula Dantas

Förderung

  • Instituto de Salud Carlos III
  • Sociedad Española de Cardiología
  • Ministerio de ciencia Innovacion y Universidades
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Centres de Recerca de Catalunya
  • European Regional Development Fund
  • Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas

Zitieren

APA

Bobi, J., Jimenez-Trinidad, F. R., Ortega-Paz, L., Cortes-Serra, N., Lazaro, I., Rodriguez, J. J., Fernandez-Becerra, C., García-Álvarez, A., Sabate, M., Brugaletta, S., & Dantas, A. P. (2025). Antiangiogenic effect of circulating extracellular vesicles in acute coronary syndrome: Role of miR‐199a‐3p and miR‐125a‐5p. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70022

Vancouver

Bobi J, Jimenez-Trinidad FR, Ortega-Paz L, Cortes-Serra N, Lazaro I, Rodriguez JJ, et al. Antiangiogenic effect of circulating extracellular vesicles in acute coronary syndrome: Role of miR‐199a‐3p and miR‐125a‐5p. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70022

BibTeX
@article{Bobi2025,
  author = {Bobi, Joaquin and Jimenez-Trinidad, Francisco-Rafael and Ortega-Paz, Luis and Cortes-Serra, Nuria and Lazaro, Iolanda and Rodriguez, Juan-Jose and Fernandez-Becerra, Carmen and García-Álvarez, Ana and Sabate, Manel and Brugaletta, Salvatore and Dantas, Ana-Paula},
  title = {Antiangiogenic effect of circulating extracellular vesicles in acute coronary syndrome: Role of miR‐199a‐3p and miR‐125a‐5p},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.70022}
}
Kostenlos starten →